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Structure-Based Design of a Macrocyclic PROTAC
Andrea Testa, Scott J. Hughes, Xavier Lucas, Jane E. Wright und Alessio Ciulli*
Abstract: Constraining a molecule in its bioactive conforma-
tion via macrocyclization represents an attractive strategy to
rationally design functional chemical probes. While this ap-
proach has been applied to enzyme inhibitors or receptor an-
tagonists, to date it remains unprecedented for bifunctional
molecules that bring proteins together, such as PROTAC de-
graders. Herein, we report the design and synthesis of a ma-
crocyclic PROTAC by adding a cyclizing linker to the BET
degrader MZ1. A co-crystal structure of macroPROTAC-
1 bound in a ternary complex with VHL and the second bro-
modomain of Brd4 validated the rational design. Biophysical
studies revealed enhanced discrimination between the second
and the first bromodomains of BET proteins. Despite a 12-fold
loss of binary binding affinity for Brd4, macroPROTAC-1 ex-
hibited cellular activity comparable to MZ1. Our findings
support macrocyclization as an advantageous strategy to en-
hance PROTAC degradation potency and selectivity between
homologous targets.
Introduction
Targeted protein degradation is a powerful new modality
of chemical biology and drug discovery.[1,2] PROTACs are
bifunctional molecules composed of a ligand for a target
protein of interest, and a ligand for an E3 ubiquitin ligase,
joined by a flexible linker. Recruitment of a protein close to
an E3 ligase hijacks the ligase catalytic activity, leading to the
tagging of the target protein by ubiquitination and subsequent
proteasomal degradation.[3–5] PROTACs are emerging as at-
tractive chemical probes and therapeutics, defined by a cata-
lytic and sub-stoichiometric rather than occupancy-based
mode of action, leading to an extended duration of action.[6–9]
Due to their different mechanism of action via formation of
a ternary complex species, PROTACs have the potential to
pharmacologically differentiate from inhibitors and to more
effectively impact biology and disease, including targeting
proteins that have proven intractable to other approaches.
Structural and biophysical investigation of ternary com-
plexes from our laboratory revealed that proximity-induced
formation of de novo interactions within the ternary complex
are an important feature of the PROTAC mode of action.[10]
Neomorphic interactions include protein–protein interactions
(PPIs) between the ligase and the target, which can lead to the
formation of cooperative and stable ternary complexes.[11]
These characteristics of the ternary complex, albeit not
strictly essential for PROTAC-mediated protein degrada-
tion,[12,13] are important because they can increase the popu-
lation of the complex (the key Michaelis–Menten species in
the PROTAC-mediated catalytic process) and contribute to
enhancing its thermodynamic stability and kinetic dissociative
half-life.[10,14,15] These features in turn enhance the catalytic
efficiency of the process, leading to greater levels of target
ubiquitination, and consequently faster and more prolonged
target degradation.[15,16] Because the PROTAC-induced PPIs
involve less-conserved regions outside of the ligand-binding
pocket, PROTACs made of promiscuous or non-selective
target ligands can discriminate between highly homologous
target proteins in a way not achievable with the parent in-
hibitors alone.[7,10,13,15,17,18]
Knowledge of the PROTAC binding mode in a ternary
complex, ideally from co-crystal structures, provides an op-
portunity to rationally design compounds to better fit and
stabilize the newly created interface within the ternary com-
plex, using structure-based drug design.[10,13,19,20] Our first
crystal structure of the PROTACMZ1 in complex with the E3
ligase VHL and its target, the second bromodomain (BD2) of
the bromodomain and extra-terminal motif (BET) protein,
Brd4, revealed that the two ligand moieties of MZ1 (the VHL
ligand, VH032, and the BET inhibitor, JQ1) lay in close
spatial proximity within the ternary complexes.[10] We thus
imagined that a macrocyclic PROTAC could be designed
based on the crystal structure as a strategy to lock the PRO-
TAC conformation in the bound state. Macrocyclization is
expected to reduce the energetic penalty to adopt the bound
state through conformational restriction.[21,22] As such, ma-
crocycles provide privileged scaffolds to target PPIs and
protein surfaces, amongst other challenging targets.[23–25] For
example, the archetypal macrolide natural products cyclo-
sporine and rapamycin are macrocyclic molecules that act as
molecular glues to induce the formation of a ternary com-
plex.[26,27] To our knowledge, however, the use of ma-
crocylization as a strategy for PROTAC design, or more
generally to bias recruitment of proteins together, remains
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unprecedented. Herein, we provide first proof-of-concept
validation of the approach with a macrocyclic PROTAC. The
design strategy was aided by computational calculations and
molecular dynamics (MD) simulations based on the
VHL:MZ1:BRD4BD2 ternary-complex crystal structure. Ma-
crocyclization was achieved by adding a second linker to
„close a circle“ between the two ligand moieties of MZ1.
Using isothermal titration calorimetry (ITC), fluorescence
polarization (FP), and X-ray crystallography, we show that
macroPROTAC-1 better discriminates between the recruit-
ment of the second and the first BET bromodomains to VHL.
Despite a greater than 10-fold loss in binary binding affinity
for Brd4, macroPROTAC-1 exhibits rapid and potent in-
tracellular degradation of Brd4, and cytotoxicity in BET-
sensitive cancer cell lines that are comparable to MZ1.
Results and Discussion
Inspired and guided by the crystal structure of the ternary
complex between our BET degrader MZ1, VHL, and
Brd4BD2,[10] we designed a series of macrocyclic PROTACs
with the aim to lock the PROTAC in the bound conformation
(Figure 1A). We hypothesized that macrocyclization would
increase the energetic bias towards the productive PROTAC
ternary complex, relative to either non-productive ternary
complexes (namely, those that do not lead to target ubiqui-
tination), binary complexes, or free in solution. Our approach
to cyclize MZ1 relied upon identifying a suitable vector and
linker that would retain the binding mode of the linear
compound and at the same time maintain the induced PPIs
that contribute to forming a stable and cooperative ternary
complex that underpins the preferential degradation of
BRD4.[10,15] Two vectors connecting a phenolic group on the
VHL ligand to the same carbon of the first PEG unit of the
MZ1 linker were explored (vectors A and B, Figure 1B).
We first studied computationally the potential energy
strain introduced by alkylation in vectors A and B in the JQ1-
amide (Figure 1B), using the model compound N-ethylace-
tamide (Figure 1C).[28] We observed that the alkylamide tor-
sion angles in the crystal structure of MZ1 (1108 and 1128)[10]
are low-energy states in the surrogate N-ethylacetamide. Al-
kylation at vector A would force the amide to an eclipsed
conformer, for which we found an energy penalty of ap-
proximately 5 kcalmol1. This modification would prevent
the adoption of the crystallographic pose of the MZ1 linker,
thereby disrupting the binding mode. We therefore deemed
a derivatization from vector B to be more suitable. Molecular
modelling studies were performed on derivatives 1 and 2
(Supporting Information, Figure S1A) cyclized from vector B
with a linker comprising 3 and 2 PEG units, respectively. The
modelling indicated that a 2-PEG linker, as in compound 2
(Supporting Information, Figure S1A), would be too short to
cover the distance between the two attachment points and
would impair binding of the MZ1 core (Supporting In-
formation, Figure S1B). In contrast, a linker comprising 3
PEG units (compound 1, Supporting Information, Fig-
ure S1A) could be well accommodated in the cavity formed
between the proteins (Supporting Information, Figure S1C).
We next performed molecular dynamics (MD) simulations of
1 bound to VHL and BRD4BD2 in order to investigate the
behavior of the ternary system in solution. The ternary com-
plex remained stable throughout the simulation, with reten-
tion of the binding mode for the MZ1 portion of 1 and con-
servation of the interprotein and protein–PROTAC contacts
observed in the VHL:MZ1:BRD4BD2 structure (Supporting
Information, Figures S2 and S3). Crucially, the simulations
suggested that macrocyclization was compatible with key
polar interactions at each end of the new linker, including the
water-mediated interaction of the JQ1-amide with
N433BRD4(BD2), the H-bond of the oxygen atom in the first
PEG unit in MZ1 with H437BRD4(BD2), and the H-bond with
Y98VHL (Figure 1D). Only a very modest shortening between
the attachment points was observed in the macrocycle (7.7
0.3 , Supporting Information, Figure S2A) compared to
MZ1 (7.9  and 8.2  in the two instances of the asymmetric
unit),[10] as well as the formation of a stable water network at
the proteins–PROTAC interface contributed by polar inter-
actions with each partner (Supporting Information, Fig-
ure S3B). Thus, we selected 1 as the target macrocyclic der-
ivative of MZ1 for synthesis.
In order to synthetically achieve our macrocyclic PRO-
TAC 1, a bespoke linker able to connect the BET ligand to the
two different attachment points on the VHL ligand needed to
be designed. We envisaged a retrosynthetic strategy based on
the O-alkylation of the VHL ligand with a trifunctional PEG
linker bearing a carboxylic acid for the macrolactamization
and a protected amine for coupling to JQ1. The new stereo-
center generated from the formal alkylation of the first eth-
ylene glycol unit of MZ1 could be easily set by choosing the
correct chiral glycerol equivalent. The synthesis of the tri-
functional linker is detailed in Scheme 1 and started from
commercially available (S)-(+)-1,2-isopropylideneglycerol 3
and 2-(2-(benzyloxy)ethoxy)ethyl 4-methylbenzen-
esulfonate 4. Alkylation was performed in solid–liquid phase
transfer catalysis (S-L PTC) conditions using potassium hy-
droxide as a base and tetrabutylammonium iodide as catalyst
and afforded compound 5 in 52% yield. The acetonide de-
protection was achieved in aqueous acetic acid to obtain the
diol 6 in quantitative yield. Selective primary alcohol pro-
tection with tert-butyl dimethyl silyl chloride afforded the
TBS ether 7, which underwent functional-group interconver-
sion via mesylate to obtain the azide 8. Subsequent de-
protection of the silyl ether and alkylation with mesylate 9 led
to the trityl-protected compound 10 in excellent yield. Re-
moval of the trityl group was achieved with diluted TFA and
triisopropyl silane (10% in DCM) to afford alcohol 11.
Reaction with tert-butyl bromoacetate in PTC conditions led
to ester 12 in 71% yield. Hydrogenative palladium-catalyzed
debenzylation and azide reduction, followed by Alloc pro-
tection afforded the key trifunctional linker 13.
With the trifunctional linker in hand, we next proceeded
to alkylate the Boc-protected VHL ligand 15. The mesy-
late 14 (obtained from 13 and mesyl chloride) was reacted
with 15 and potassium carbonate in DMF to give com-
pound 16 in 64% yield. The latter was treated with TFA to
simultaneously deprotect the tert-butyl ester and the Boc
protecting group. After exchanging the trifluoroacetate
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counterion with hydrochloride by freeze drying from a diluted
HCl solution, macrolactamization was performed with HA-
TU in high dilution (1.7 mm in DCM) to afford compound 17
in 75% yield. Alloc deprotection was achieved with tetraki-
s(triphenylphosphine)palladium and an excess of phenylsi-
lane. Finally, amide coupling with JQ1-COOH in the presence
of COMU and DIPEA afforded compound 1 in 32% isolated
yield from 17 (Scheme 2).
To assess the extent to which macrocyclization impacted
on the formation of PROTAC ternary complexes between
VHL and BET bromodomains, we next turned to biophysical
ternary complex assays. First, we performed a competitive
fluorescence polarization (FP) assay.[15] In this assay, a fluo-
Figure 1. Structure-based design of macrocyclic PROTAC 1. A) Crystal structure of MZ1 in complex with Brd4BD2 and VHL-EloB-EloC shows MZ1
in a horseshoe shape, suggesting potential for cyclization (PDB code 5T35).[10] B) The two cyclization vectors „A“ and „B“ investigated computa-
tionally in this study. In black the chemical structure of MZ1, in red the additional linker. C) Torsional energy profiling along the alkylamide
dihedral of N-ethylacetamide (blue) and N-isopropylacetamide (orange and green), as surrogates of the chemical environment in the linker of
MZ1 and its macrocyclic derivatives. D) Chemical structure of 1 and its non-covalent interactions with VHL (residues in red), BRD4BD2 (residues
in black) and water (red spheres), as observed during the last 50 ns of a 200 ns MD simulation of the VHL:1:BRD4BD2 ternary complex. The
percentage of time spent in the interaction is shown. Charged, polar, and hydrophobic amino acids are colored in purple, blue, and green, respec-
tively, and the solvent-exposure of atoms in 1 is highlighted in a gray shadow.
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rescent HIF-1a peptide probe bound to VHL is displaced in
a dose-responsive fashion by either PROTAC alone or
PROTAC pre-incubated with individual BET bromodomains.
Positive cooperativity (a) would result in a left-shift of the
curve (higher binding affinity) in the presence of the bro-
modomain. Compound 1 (herein referred to as macro-
PROTAC-1) retained high binding affinity to VHL (Ki=
33 nm, Figure 2A). We observed cooperative formation of
ternary complexes with the BD2s of Brd4, Brd2 and, to
a lesser extent, Brd3 (a= 10.5, 9.5, and 4.0, respectively). In
contrast, no cooperativity was observed with the first bro-
modomain (BD1) of Brd3, Brd4, and Brd2 (a= 0.9, 0.8, and
Scheme 1. Synthesis of trifunctional linker 13. i) 2-(2-(benzyloxy)ethoxy)ethyl 4-methylbenzenesulfonate (4), KOH, TBAI, Dioxane; ii) 80% AcOH in
H2O; iii) TBSCl, TEA, DMAP, DCM; iv) MsCl, Py; v) NaN3, DMF; vi) TBAF, THF; vii) 2-(2-(trityloxy)ethoxy)ethyl methanesulfonate (9), KOH, TBAI,
Dioxane; viii) 10% TFA/TIPS in DCM; ix) tert-butyl 2-bromoacetate, TBAB, 37% NaOH in H2O; x) H2, Pd/C, AcOH, EtOH; N-(allyloxycarbonylo-
xy)succinimide, NaHCO3, dioxane/H2O (2:1).
Scheme 2. Macrolactamization and completion of the synthesis of macroPROTAC-1. i) K2CO3, DMF; ii) TFA, DCM; iii) HCl, H2O; iv) HATU,
DIPEA, DMF; v) Pd(PPh3)4, PhSiH3, THF; vi) JQ1-COOH, COMU, DIPEA, DMF.
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0.7, respectively). This contrasts with MZ1, which could still
form cooperative complexes with all the target bromodo-
mains,[10,15] and suggests that macroPROTAC-1 better diffe-
rentiates the second bromodomains versus the first bromo-
domains of the BET proteins compared to MZ1.
To gain more insights on the effect of cyclization on the
thermodynamics of ternary-complex formation, the binding
affinity of macroPROTAC-1 for VHL and selected BET
bromodomains was studied by ITC (Supporting Information,
Figure S4). For these experiments, among the six BET bro-
modomains, we selected Brd2BD1 and Brd4BD2 as they res-
pectively formed the least cooperative and most cooperative
ternary complexes, according to our FP data. Macro-
PROTAC-1 bound to VHL with Kd= 47 9 nm and DH of
6.7 0.2 kcalmol1 (Figure 2B), comparable to MZ1 (Kd=
66 6 nm and DH of 7.7 0.3 kcalmol1).[10] Interestingly,
much weaker binary binding affinities were detected for the
bromodomains (Brd4BD2 Kd= 180 nm, compared with 15 nm
for MZ1; Brd2BD1 Kd= 740 nm, compared with 62 nm for
MZ1, Table 1), corresponding to a 12-fold loss of binary af-
finity compared to MZ1 in each case.[10] Thermodynamics of
formation of ternary complexes VHL:1:Brd2BD1 and
VHL:1:Brd4BD2 revealed high positive cooperativity of VHL–
Brd4BD2 (a= 20, compared with 17.6 for MZ1) and a nega-
tively cooperative complex with VHL–Brd2BD1 (a= 0.7,
compared with 2.9 for MZ1, Figure 2B and Table 1). To-
gether, the biophysical data is consistent with a better dis-
crimination between the highly homologous BET bromodo-
mains when using macroPROTAC-1 compared to its non-
cyclic progenitor.
To validate the binding mode and deepen understanding
of the molecular basis for the biophysical properties of ma-
croPROTAC-1, we next co-crystallized VHL:macro-
PROTAC-1:Brd4BD2 and solved the structure of the ternary
complex at a resolution of 3.5  (Figure 3 and Supporting
Information, Figure S5). The structure superposes well with
the ternary complex VHL:MZ1:Brd4BD2 (CaRMSD= 0.6 )
and recapitulates the major PPIs between VHL and Brd4BD2.
Figure 2. Binding affinity and cooperativity of ternary complex formation. A) Dose-dependent displacement of a fluorescent HIF-1a peptide by
1 alone or 1 in complex with a BET bromodomain, measured by fluorescence polarization. Cooperative binding is observed for all the BD2s while
slightly negatively cooperative binding is observed for the BD1s. B) Representative inverse ITC titrations of VCB into 1 and VCB into 1:Brd2BD1 or
1:Brd4BD2 showing cooperative binding in the case of Brd4BD2 and negatively cooperative binding in the case of Brd2BD1.
Tabelle 1: Thermodynamic parameters of formation of binary and ternary complexes between 1 or MZ1, and VHL–ElonginC–ElonginB (VCB), Brd2BD1,
and Brd4BD2. The reported values are the mean standard deviation from independent measurements. For titrations of MZ1, the data is taken from
ref. [10].
Protein in syringe Species in cell Kd [nm] DH [kcalmol
1] DG [kcalmol1] TDS [kcalmol1] a Total DG [kcalmol1] No. of replicates
Brd2BD1 1 743202 9.60.6 8.40.2 1.20.7 – – 2
Brd4BD2 1 18042 6.250.17 9.20.2 2.70.3 – – 2
VCB 1 479 6.70.2 10.00.1 3.30.3 – – 3
VCB 1: Brd2BD1 7032 4.80.5 9.90.4 5.00.1 0.7 18.30.4 2
VCB 1: Brd4BD2 21 10.90.2 11.90.3 1.00.4 20 21.10.4 2
Brd2BD1 MZ1 626 12.80.7 9.840.06 3.00.8 – – 2
Brd4BD2 MZ1 151 10.90.4 10.680.04 0.20.4 – – 2
VCB MZ1 666 7.70.3 9.810.05 2.10.3 – – 8
VCB MZ1: Brd2BD1 248 7.30.2 10.40.2 3.10.4 2.9 20.30.2 2
VCB MZ1: Brd4BD2 3.70.7 8.90.1 11.50.1 2.60.2 17.6 22.20.2 2
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Conserved contacts include the previously reported electro-
static interactions between Arg107VHL, Arg108VHL,
D381Brd4(BD2) and E383Brd4(BD2) ; and the stack between the
canonical WPF shelf of Brd4BD2 and Pro71 of VHL (Fig-
ure 3A). Collectively, these interactions result in a buried
surface area (BSA) between the two proteins of 681 2. The
MZ1-portion of macroPROTAC-1 binds in an identical S-
shaped conformation to the uncyclized PROTAC, retaining
the H-bond between His437Brd4(BD2) and an oxygen atom on
the PEG-3 linker. The cyclizing part of the linker optimally
fills an additional cavity created at the interface of the two
proteins next to the ZA-loop of Brd4BD2 (Figure 3A and
Supporting Information, Figure S6), which is in good agree-
ment with the MD simulations (Figure 1D and Supporting
Information, Figure S2). The BSA at the macroPROTAC-
1:VHL and macroPROTAC-1:Brd4BD2 interfaces are 961 and
1064 2, respectively, which brings the total BSA to 2686 2.
Taken together, these findings could explain the high coope-
rativity of VHL:macroPROTAC-1:Brd4BD2. Closer examina-
tion of the additional linker revealed potential clashes with
the ZA-loop, which could explain the loss in binding affinity
with the BET bromodomains. Within the ZA-loop, the side
chain of Leu387, as well as the carbonyl oxygens of both
Gly386 and Leu385, are less than 3.5  from the newly added
linker. Interestingly, the clash with Leu387 is similar to that
exploited in our bump-and-hole study for the same residue
(Figure 3B).[29,30] The enhanced discrimination between BD1
and BD2 could potentially be attributed to differences in the
ZA-loop of BD1s compared to BD2s. Sequence alignment of
the six bromodomains revealed an additional proline
(Pro397) in BD1 which could limit the ability of the BD1s to
accommodate the extra linker present in macroPROTAC-
1 (Supporting Information, Figure S7).
We next investigated the cellular activities of macro-
PROTAC-1. First, HeLa cells were treated with macro-
PROTAC-1 or MZ1 for 4 h or 18 h before cell lysis and
western blotting (Supporting Information, Figure S8). Ma-
croPROTAC-1, like MZ1, was able to induce potent and ra-
pid degradation of Brd4 (both short and long isoforms) with
a DC50 between 25 and 125 nm, while degradation of Brd2 and
Brd3 occurred only at higher concentrations, with a DC50
greater than 125 nm. Degradation of the BET protein and
downstream effects on Myc levels after treatment with ma-
croPROTAC-1 or MZ1 were next assessed in a disease-rele-
vant cell line, 22RV1 (human prostate carcinoma, Fig-
ure 4A,B). MacroPROTAC-1 induced the degradation of
more than 90% of Brd4 at 250 nm. MacroPROTAC-1 also
induced a more than 90% depletion of cellular levels of Myc
in 22RV1 cells, as downstream effect of BET degradation,
with potency and kinetics comparable to MZ1 (Figure 4A,B).
We next evaluated the impact of compound 1 on the via-
bility of BET-sensitive human prostate carcinoma 22RV1 and
acute myeloid leukemia MV4;11 cancer cell lines (Fig-
ure 4C,D). MacroPROTAC-1 induced a marked anti-
proliferative effect with an EC50 of 640 nm in 22RV1 cells
(Figure 4C and Supporting Information) and an EC50 of
300 nm in MV4;11 cells (Figure 4D and Supporting In-
formation), a potency comparable to MZ1. Compound
cisMZ1, which does not induce BET-protein degradation but
can still inhibit the BET proteins, was used as a reference
control to confirm that cytotoxicity is due to BET-protein
degradation and not inhibition.[7] Taken together, these res-
ults show that macroPROTAC-1 has a very similar cellular
activity to MZ1, despite its 12-fold weaker binary binding
affinity at the bromodomain end.
Conclusion
In conclusion, this work illustrates a successful roadmap to
macrocyclization PROTAC design strategies. Macrocycliza-
tion allows the constraint of a PROTAC molecule in its bio-
active conformation, biasing it to adopt or discriminate
against a desired ternary complex, which we show can aid
degradation potency and selectivity amongst homologous
targets. Our work also highlights that the binary binding en-
ergies of the PROTAC for the target protein (and E3 ligase)
should ideally not be detrimentally impacted as a result of the
cyclization process, and we suggest this should be monitored
closely in future applications. We anticipate that structure-
Figure 3. Crystal structure of ternary complex VHL:1:Brd4BD2. A) Superposition of VHL:1:Brd4BD2 (green and yellow) and VHL:MZ1:Brd4BD2 ternary
complex (PDB 5T35; grey) highlighting the key protein-protein interactions between VHL and Brd4BD2. B) Residues in the ZA-loop of Brd4BD2
(Leu385, Gly386 and Leu387) that are in close proximity to the additional linker on 1. Red dashes indicate atom pairs that are 3.5  apart.
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based design of macrocyclic PROTACs will be an increasingly
attractive and feasible strategy of drug design, in particular as
relevant structural information continues to emerge and im-
pact the field.[31]
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Angewandte
ChemieForschungsartikel
&&&& www.angewandte.de  2019 Die Autoren. Verçffentlicht von Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. 2019, 131, 2 – 10

These are not the final page numbers!
[9] D. P. Bondeson, A. Mares, I. E. D. Smith, E. Ko, S. Campos,
A. H. Miah, K. E. Mulholland, N. Routly, D. L. Buckley, J. L.
Gustafson, et al., Nat. Chem. Biol. 2015, 11, 611 – 617.
[10] M. S. Gadd, A. Testa, X. Lucas, K.-H. Chan, W. Chen, D. J.
Lamont, M. Zengerle, A. Ciulli, Nat. Chem. Biol. 2017, 13, 514 –
521.
[11] C. Maniaci, A. Ciulli,Curr. Opin. Chem. Biol. 2019, 52, 145 – 156.
[12] A. Zorba, C. Nguyen, Y. Xu, J. Starr, K. Borzilleri, J. Smith, H.
Zhu, K. A. Farley, W. D. Ding, J. Schiemer, et al., Proc. Natl.
Acad. Sci. USA 2018, 115, E7285 –E7292.
[13] R. P. Nowak, S. L. DeAngelo, D. Buckley, Z. He, K. A. Dono-
van, J. An, N. Safaee, M. P. Jedrychowski, C. M. Ponthier, M.
Ishoey, et al., Nat. Chem. Biol. 2018, 14, 706 – 714.
[14] S. L. Fisher, A. J. Phillips, Curr. Opin. Chem. Biol. 2018, 44, 47 –
55.
[15] M. J. Roy, S. Winkler, S. J. Hughes, C. Whitworth, M. Galant, W.
Farnaby, K. Rumpel, A. Ciulli, ACS Chem. Biol. 2019, 14, 361 –
368.
[16] K. M. Riching, S. Mahan, C. R. Corona, M. McDougall, J. D.
Vasta, M. B. Robers, M. Urh, D. L. Daniels, ACS Chem. Biol.
2018, 13, 2758 – 2770.
[17] D. P. Bondeson, B. E. Smith, G. M. Burslem, A. D. Buhimschi, J.
Hines, S. Jaime-Figueroa, J. Wang, B. D. Hamman, A. Ishchenko,
C. M. Crews, Cell Chem. Biol. 2018, 25, 78 – 87.e5.
[18] B. Jiang, E. S. Wang, K. A. Donovan, Y. Liang, E. S. Fischer, T.
Zhang, N. S. Gray, Angew. Chem. Int. Ed. 2019, 58, 6321 – 6326;
Angew. Chem. 2019, 131, 6387 – 6392.
[19] R. L. M. van Montfort, P. Workman, Essays Biochem. 2017, 61,
431 – 437.
[20] W. Farnaby, M. Koegl, M. J. Roy, C. Whitworth, E. Diers, N.
Trainor, D. Zollman, S. Steurer, J. Karolyi-Oezguer, C. Rie-
dmueller, et al., Nat. Chem. Biol. 2019, 15, 672 – 680.
[21] E. A. Villar, D. Beglov, S. Chennamadhavuni, J. A. Porco, D.
Kozakov, S. Vajda, A. Whitty, Nat. Chem. Biol. 2014, 10, 723 –
731.
[22] A. Glas, E. C. Wamhoff, D. M. Krger, C. Rademacher, T. N.
Grossmann, Chem. Eur. J. 2017, 23, 16157 – 16161.
[23] T. A. F. Cardote, A. Ciulli, ChemMedChem 2016, 11, 787 – 794.
[24] E. Valeur, S. M. Guret, H. Adihou, R. Gopalakrishnan, M.
Lemurell, H. Waldmann, T. N. Grossmann, A. T. Plowright,
Angew. Chem. Int. Ed. 2017, 56, 10294 – 10323; Angew. Chem.
2017, 129, 10428 – 10459.
[25] S. Alihodzˇic´, M. Bukvic´, I. J. Elenkov, A. Hutinec, S. Kosˇtrun, D.
Pesˇic´, G. Saxty, L. Tomasˇkovic´, D. Zˇiher, Prog.Med. Chem. 2018,
57, 113 – 233.
[26] D. Benjamin, M. Colombi, C. Moroni, M. N. Hall,Nat. Rev. Drug
Discovery 2011, 10, 868 – 880.
[27] S. A. Andrei, E. Sijbesma, M. Hann, J. Davis, G. OMahony,
M. W. D. Perry, A. Karawajczyk, J. Eickhoff, L. Brunsveld, R. G.
Doveston, et al., Expert Opin. Drug Discovery 2017, 12, 925 –
940.
[28] M. Avalos, R. Babiano, J. L. Barneto, J. L. Bravo, P. Cintas, J. L.
Jimnez, J. C. Palacios, J. Org. Chem. 2001, 66, 7275 – 7282.
[29] M. G. J. Baud, E. Lin-Shiao, T. Cardote, C. Tallant, A. Pschibul,
K.-H. Chan, M. Zengerle, J. R. Garcia, T. T. L. Kwan, F. M.
Ferguson, et al., Science 2014, 346, 638 – 641.
[30] A. C. Runcie, M. Zengerle, K. H. Chan, A. Testa, L. Van Beur-
den, M. G. J. Baud, O. Epemolu, L. C. J. Ellis, K. D. Read, V.
Coulthard, et al., Chem. Sci. 2018, 9, 2452 – 2468.
[31] Atomic coordinates and structure factors for the crystal struc-
ture VCB:1:Brd4BD2 have been deposited in the PDB under
accession number 6SIS.
Manuskript erhalten: 11. November 2019
Akzeptierte Fassung online: 19. November 2019
Endgltige Fassung online: &&. && &&&&
Angewandte
ChemieForschungsartikel
&&&&Angew. Chem. 2019, 131, 2 – 10  2019 Die Autoren. Verçffentlicht von Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.de
These are not the final page numbers! 
Forschungsartikel
Wirkstoff-Design
A. Testa, S. J. Hughes, X. Lucas,
J. E. Wright, A. Ciulli* &&&&—&&&&
Structure-Based Design of a Macrocyclic
PROTAC
Eine makrocyclische PROTAC wurde ent-
wickelt, indem ein cyclisierender Linker
zu MZ1 – einer PROTAC, die auf die
Bromodomne des BET-Proteins, Brd4,
abzielt – angefgt wurde. Eine Cokris-
tallstruktur von macroPROTAC-1, die in
einem ternren Komplex mit der E3-
Ligase VHL und der zweiten Bromodo-
mne des Brd4-Proteins gebunden ist,
validierte das rationale Design. Diese
Makrocyclisierungsstrategie erhçhte die
Zielspezifitt und die zellulre Aktivitt
der PROTAC.
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